Skip to content

Clinical values of Circulating Tumor Cells in patients with advanced non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy

Clinical values of Circulating Tumor Cells in patients with advanced non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-13003475
Enrollment
Unknown
Registered
2013-05-10
Start date
2013-05-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

non-small lung cacer:NA

Sponsors

Tongji University Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed NSCLC; 2. Normal physiological functions of the viscera as heart, liver, kidney and bone marrow; 3. ECOG performance status 0-1; 4. Life expectancy of at least 3 months; 5. At least one measurable lesion; 6. Aged 18-80 years; 7. Patients prepared for platinum-based chemotherapy with signed informed consent; 8. CTC counts of more than 8.5 CU in 3mL blood before therapy.

Exclusion criteria

Exclusion criteria: 1. Concurrent other cancers or other serious diseases (except for non-melanoma skin cancer and in situ cervical cancers) within 5 years prior to study enrollment; 2. Previous anti-cancer therapy within 6 months prior to study enrollment; 3. Symptomatic brain metastases, uncontrolled serious effusions; 4. Inability to comply with study and/or follow-up procedures; Inability to obtain informed consent.

Design outcomes

Primary

MeasureTime frame
CTC;

Countries

China

Contacts

Public ContactCaicun Zhou
caicunzhou@yahoo.com.cn+86 21 65115006-3049

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026